Logo image of OCGN

OCUGEN INC (OCGN) Stock Fundamental Analysis

NASDAQ:OCGN - Nasdaq - US67577C1053 - Common Stock - Currency: USD

0.8342  -0.05 (-5.57%)

After market: 0.835 +0 (+0.1%)

Fundamental Rating

2

OCGN gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 560 industry peers in the Biotechnology industry. OCGN may be in some trouble as it scores bad on both profitability and health. OCGN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OCGN had negative earnings in the past year.
In the past year OCGN has reported a negative cash flow from operations.
In the past 5 years OCGN always reported negative net income.
OCGN had a negative operating cash flow in each of the past 5 years.
OCGN Yearly Net Income VS EBIT VS OCF VS FCFOCGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

OCGN has a worse Return On Assets (-107.67%) than 78.21% of its industry peers.
Looking at the Return On Equity, with a value of -436.12%, OCGN is doing worse than 77.68% of the companies in the same industry.
Industry RankSector Rank
ROA -107.67%
ROE -436.12%
ROIC N/A
ROA(3y)-79.4%
ROA(5y)-83.76%
ROE(3y)-144.88%
ROE(5y)-130.94%
ROIC(3y)N/A
ROIC(5y)N/A
OCGN Yearly ROA, ROE, ROICOCGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OCGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OCGN Yearly Profit, Operating, Gross MarginsOCGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K

More info and screens

2

2. Health

2.1 Basic Checks

OCGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OCGN has more shares outstanding
OCGN has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, OCGN has a worse debt to assets ratio.
OCGN Yearly Shares OutstandingOCGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
OCGN Yearly Total Debt VS Total AssetsOCGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -7.49, we must say that OCGN is in the distress zone and has some risk of bankruptcy.
OCGN has a Altman-Z score of -7.49. This is in the lower half of the industry: OCGN underperforms 68.93% of its industry peers.
OCGN has a Debt/Equity ratio of 1.74. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of OCGN (1.74) is worse than 81.61% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.74
Debt/FCF N/A
Altman-Z -7.49
ROIC/WACCN/A
WACC9.43%
OCGN Yearly LT Debt VS Equity VS FCFOCGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

OCGN has a Current Ratio of 2.60. This indicates that OCGN is financially healthy and has no problem in meeting its short term obligations.
OCGN has a Current ratio of 2.60. This is in the lower half of the industry: OCGN underperforms 68.57% of its industry peers.
OCGN has a Quick Ratio of 2.60. This indicates that OCGN is financially healthy and has no problem in meeting its short term obligations.
With a Quick ratio value of 2.60, OCGN is not doing good in the industry: 66.61% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 2.6
Quick Ratio 2.6
OCGN Yearly Current Assets VS Current LiabilitesOCGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

OCGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.64%, which is quite good.
The Revenue for OCGN has decreased by -21.48% in the past year. This is quite bad
EPS 1Y (TTM)13.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)-21.48%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%46.06%

3.2 Future

OCGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.22% yearly.
OCGN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 191.39% yearly.
EPS Next Y-32.87%
EPS Next 2Y-12.72%
EPS Next 3Y23.7%
EPS Next 5Y52.22%
Revenue Next Year-79.42%
Revenue Next 2Y-68.18%
Revenue Next 3Y209.94%
Revenue Next 5Y191.39%

3.3 Evolution

OCGN Yearly Revenue VS EstimatesOCGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
OCGN Yearly EPS VS EstimatesOCGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OCGN. In the last year negative earnings were reported.
Also next year OCGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OCGN Price Earnings VS Forward Price EarningsOCGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OCGN Per share dataOCGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05 -0.1 -0.15 -0.2

4.3 Compensation for Growth

A more expensive valuation may be justified as OCGN's earnings are expected to grow with 23.70% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-12.72%
EPS Next 3Y23.7%

More info and screens

0

5. Dividend

5.1 Amount

OCGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

OCUGEN INC

NASDAQ:OCGN (5/29/2025, 8:01:49 PM)

After market: 0.835 +0 (+0.1%)

0.8342

-0.05 (-5.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/bmo
Earnings (Next)08-06 2025-08-06
Inst Owners24.75%
Inst Owner Change8.02%
Ins Owners0.95%
Ins Owner Change-5.96%
Market Cap243.61M
Analysts82
Price Target6.89 (725.94%)
Short Float %23.66%
Short Ratio18.03
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.69%
Min EPS beat(2)6.63%
Max EPS beat(2)14.75%
EPS beat(4)4
Avg EPS beat(4)13.98%
Min EPS beat(4)6.63%
Max EPS beat(4)26.47%
EPS beat(8)7
Avg EPS beat(8)17.79%
EPS beat(12)9
Avg EPS beat(12)13.57%
EPS beat(16)9
Avg EPS beat(16)-226.22%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 44
P/FCF N/A
P/OCF N/A
P/B 15.31
P/tB 15.31
EV/EBITDA N/A
EPS(TTM)-0.19
EYN/A
EPS(NY)-0.24
Fwd EYN/A
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0.02
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -107.67%
ROE -436.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.4%
ROA(5y)-83.76%
ROE(3y)-144.88%
ROE(5y)-130.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 1.74
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 38.88%
Cap/Sales 18.95%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.6
Quick Ratio 2.6
Altman-Z -7.49
F-Score3
WACC9.43%
ROIC/WACCN/A
Cap/Depr(3y)863.08%
Cap/Depr(5y)672.89%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-32.87%
EPS Next 2Y-12.72%
EPS Next 3Y23.7%
EPS Next 5Y52.22%
Revenue 1Y (TTM)-21.48%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%46.06%
Revenue Next Year-79.42%
Revenue Next 2Y-68.18%
Revenue Next 3Y209.94%
Revenue Next 5Y191.39%
EBIT growth 1Y-15.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.52%
OCF growth 3YN/A
OCF growth 5YN/A